“Lindys Health’s involvement in this study underpins our commitment to helping our partners bring safe and effective dermatological therapies to market. Inflammatory acne can significantly diminish quality of life,” states Michael Young, co-founder of Lindus Health. “We are enthusiastic about the opportunity to leverage our unique technical and service-based capabilities in another dermatology study, building on our vast experience in this space.”

“This study highlights the core underlying mechanism of action of our ovarian support cells in maturing eggs outside of the body and provides a deeper look into the role that Fertilo plays in promoting high quality egg maturation for IVF treatment,” said Dr. Christian Kramme, Chief Scientific Officer of Gameto.

“These results demonstrate a marked change in how physicians will be able to diagnose and recommend treatment for prostate cancer patients,” said Avenda Health CEO Shyam Natarajan, PhD. “By increasing the confidence in which we can predict a tumor’s margins, patients and their doctors will have increased certainty that their entire tumor is treated and with the appropriate intervention in correlation to the severity of their case.”

The data presented highlights the strong predictive value of oxidative stress biomarker (4-HNE) levels with the rate of disease progression and survival in ALS patients from a longitudinal patient registry cohort.

Peter Sackey further elaborated: “Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025”.